Cancer Research includes companies working on scientific research aimed at understanding the causes, prevention, diagnosis, treatment, and potential cures for cancer. It includes many disciplines, from biology and genetics, to clinical trials and drug development, with the ultimate goal of improving cancer care and outcomes. Cancer research companies are developing life-saving treatments and diagnostics for a growing market in high demand. These companies constantly innovate, have a global reach, and form important strategic partnerships, which makes them appealing to investors looking for profits and supporting health progress.
Buy Rating on Merck & Co. Affirmed by Daina Graybosch Amidst WINREVAIR's Market Potential and Efficacy
Merck CEO on Winrevair Approval, Obesity Drug, Health Costs
Merck Chair and CEO Robert M. Davis discusses the US approval of Winrevair, a new treatment for a rare, dangerous form of high blood pressure. Speaking on Bloomberg Television, Davis also comments on Merck's development of an obesity-fighting drug and health-care costs. (Video edited to remove incorrect graphic.)
Phase 3 trial of Bristol-Myers Squibb (BMY.US) drug Zeposia for Crohn's disease failed
Bristol-Myers Squibb said that the phase 3 study of its drug Zeposia to treat moderate to severe active Crohn's disease failed to reach the main clinical remission end in week 12.
Morningstar Unveils 10 Cheap Stocks With Big Moats
Form 144 | Blueprint Medicines(BPMC.US) Officer Proposes to Sell 475K in Common Stocks
SEC FILLINGS DISCLOSED/ Mar 28, $Blueprint Medicines(BPMC.US)$ Officer MICHAEL LANDSITTEL intends to sell 5,000 shares of its common stock on Mar 28, with a total market value of approximately $475K.
Merck (MRK) Rises Higher Than Market: Key Facts